Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TNXP
stocks logo

TNXP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
2.90M
+12.32%
-4.175
-57.27%
21.90M
+801.61%
-3.160
+11.27%
37.10M
+1756.86%
-2.730
-29.27%
Estimates Revision
The market is revising No Change the revenue expectations for Tonix Pharmaceuticals Holding Corp. (TNXP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -26.41%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-26.41%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Tonix Pharmaceuticals Holding Corp (TNXP.O) is -1.61, compared to its 5-year average forward P/E of -1.31. For a more detailed relative valuation and DCF analysis to assess Tonix Pharmaceuticals Holding Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.31
Current PE
-1.61
Overvalued PE
0.17
Undervalued PE
-2.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.99
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.74
Undervalued EV/EBITDA
-9.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.64
Current PS
0.00
Overvalued PS
4.12
Undervalued PS
-0.84
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

TNXP News & Events

Events Timeline

(ET)
2025-11-24
07:11:47
Tonix Pharmaceuticals Obtains IND Approval for Phase 2 Trial of TNX-102 SL
select
2025-11-17 (ET)
2025-11-17
07:11:02
Tonix Pharmaceuticals Declares TONMYA Now Available for Purchase in the U.S.
select
2025-11-04 (ET)
2025-11-04
07:43:43
Tonix Pharmaceuticals Partners with MGH for Collaboration
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-24Newsfilter
Tonix Receives FDA Clearance for Phase 2 Study of TNX-102 SL in Major Depressive Disorder
  • Clinical Trial Launch: Tonix Pharmaceuticals announced FDA clearance to initiate the pivotal Phase 2 HORIZON study of TNX-102 SL in mid-2026 for adults with major depressive disorder. The study aims to enroll approximately 360 patients to assess the drug's efficacy and safety.
  • Market Demand: Over 21 million adults in the U.S. experience a major depressive episode each year, highlighting the urgent need for innovative treatment options. TNX-102 SL's unique pharmacological profile targets sleep disturbances associated with depression, potentially offering new therapeutic avenues for patients.
  • Study Design: The HORIZON study will utilize a randomized, double-blind, placebo-controlled design, with the primary endpoint being the change in MADRS score over six weeks. This design will help Tonix validate TNX-102 SL as a first-line monotherapy, advancing its application in the depression market.
  • Drug Background: TNX-102 SL is a sublingual tablet that has shown potential in improving depressive symptoms in studies for fibromyalgia and PTSD. The drug's patent protection is expected to last until 2034, potentially providing Tonix with a competitive edge in the depression treatment landscape.
[object Object]
Preview
9.0
11-24SeekingAlpha
Tonix Pharmaceuticals Receives FDA Approval to Advance TNX-102 for Depression Treatment

  • FDA Approval: Tonix Pharmaceuticals has received clearance from the U.S. FDA for its investigational new drug application for TNX-102 SL 5.6 mg, aimed at treating major depressive disorder.

  • Clinical Development Plans: The company plans to initiate a pivotal mid-stage trial for TNX-102 SL targeting adults with major depressive disorder around mid-2026.

[object Object]
Preview
9.0
11-17Benzinga
Reasons Behind the Surge in Tonix Pharmaceuticals (TNXP) Stock on Monday Morning

  • New Drug Launch: Tonix Pharmaceuticals has announced the U.S. commercial availability of TONMYA, the first FDA-approved treatment for fibromyalgia in over 15 years, aimed at the 10 million U.S. adults affected by the condition.

  • Positive Market Reaction: Following the announcement, shares of Tonix Pharmaceuticals (TNXP) rose by 6.48%, reflecting investor optimism about the new revenue driver for the company.

  • Clinical Success: The FDA approved TONMYA after two Phase 3 trials showed significant pain reduction compared to placebo, marking a significant milestone for the company.

  • Investment Opportunities: Investors can acquire TNXP shares through brokerage platforms or ETFs that include the stock, providing exposure to the healthcare sector trends.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tonix Pharmaceuticals Holding Corp (TNXP) stock price today?

The current price of TNXP is 19.53 USD — it has increased 9.84 % in the last trading day.

arrow icon

What is Tonix Pharmaceuticals Holding Corp (TNXP)'s business?

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

arrow icon

What is the price predicton of TNXP Stock?

Wall Street analysts forecast TNXP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNXP is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tonix Pharmaceuticals Holding Corp (TNXP)'s revenue for the last quarter?

Tonix Pharmaceuticals Holding Corp revenue for the last quarter amounts to 3.29M USD, increased 16.58 % YoY.

arrow icon

What is Tonix Pharmaceuticals Holding Corp (TNXP)'s earnings per share (EPS) for the last quarter?

Tonix Pharmaceuticals Holding Corp. EPS for the last quarter amounts to -3.59 USD, decreased -84.31 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tonix Pharmaceuticals Holding Corp (TNXP)'s fundamentals?

The market is revising No Change the revenue expectations for Tonix Pharmaceuticals Holding Corp. (TNXP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -26.41%.
arrow icon

How many employees does Tonix Pharmaceuticals Holding Corp (TNXP). have?

Tonix Pharmaceuticals Holding Corp (TNXP) has 81 emplpoyees as of December 05 2025.

arrow icon

What is Tonix Pharmaceuticals Holding Corp (TNXP) market cap?

Today TNXP has the market capitalization of 209.15M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free